VISEN Pharmaceuticals (FRA:T06) Dividends Received

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:T06 VISEN Pharmaceuticals FRA:T06
7 GF Score
Price €2.06
! 5 Warning Signs
View Full Analysis

What is VISEN Pharmaceuticals Dividends Received?

Dividends Received only applicable to companies reporting Cash Flow from Operations in direct method.

FRA:T06
7GF Score
VISEN Pharmaceuticals FRA:T06
Dividends Received is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

VISEN Pharmaceuticals Business Description

Other Exchanges 02561:Hong Kong
Address 69 Jiuzhang Road, Suite 3-108, Floor 3, Building B, Hengtai Lixiang Chuangxin Tower, Suzhou, CHN
VISEN Pharmaceuticals is a late-stage, near-commercialization biopharmaceutical company focused on providing treatments in selected endocrinology diseases in China. It has one Core Product and two other pipeline drug candidates. Its Core Product, lonapegsomatropin, is a once-weekly long-acting growth hormone replacement therapy for the treatment of pediatric growth hormone deficiency (PGHD), a common short stature in patients aged under 18 caused by insufficient growth hormone. TransCon CNP (navepegritide), one of its key drug candidates, is a long-acting prodrug of c-type natriuretic peptide for the treatment of achondroplasia (ACH), a short-limbed dwarfism that results in severe skeletal complications and comorbidities.
7GF Score

Get the complete analysis for FRA:T06

Dividends Received is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.06
Price